Impacting millions of families and devouring billions of dollars globally, Alzheimer's disease is the focus of exhaustive research to find a cure. Although intensely investigated over the last three decades using cutting-edge technologies, the "pathogenic cause" of Alzheimer's disease has not been found.

A vampire-like bacteria that leeches onto specific other bacteria - including certain human pathogens - has the potential to serve as a living antibiotic for a range of infectious diseases, a new study indicates.

Oxaliplatin, a platinum-based anticancer drug that's made enormous headway in recent years against colorectal cancer, appears to cause nerve damage that may be permanent and worsens even months after treatment ends.

In a cancer treatment breakthrough 20 years in the making, researchers from the University of Pennsylvania's Abramson Cancer Center and Perelman School of Medicine have shown sustained remissions of up to a year among a small group of advanced chronic lymphocytic leukemia (CLL) patients treated with genetically engineered versions of their own T cells.

In the frame of the European Project CONTRACT, which aims at analysing, improving and harmonising "informed consent" across Europe a questionnaire has been set up which will analyse the current situation concerning the legal, ethical, technical and clinical handling of consent, mainly in European projects dealing with vulnerable patient groups.

The Innovative Medicines Initiative (IMI), currently the largest public-private partnership in the biopharmaceutical sector, launches its second wave of research projects which address key areas including cancer, immune-mediated diseases, infectious disorders and electronic health.

Pharmaceutical and healthcare market research company Manhattan Research recently released the ePharma Consumer® v10.0 study, which explores the online behaviors of ePharma Consumers, or U.S. consumers using the Internet for prescription drug information.